GAUDIUMIVF

- Intimation for closure of trading window for designated persons and their relatives. - Effective from July 01, 2026, until 48 hours after the announcement of Q1 FY27 (June 30, 2026) financial results. - Board meeting date for results to be intimated separately.

- Corrigendum filed for inadvertent regrouping and typographical errors in the Consolidated Financial Results for the year ended March 31, 2025 (comparative figures). - The corrections are clerical and do not impact Profit After Tax, Net Worth, or the overall financial position for the current year ended March 31, 2026. - Minor adjustment to Profit After Tax for FY25 from ₹1,917.73 Lakhs to ₹1,917.86 Lakhs. - Standalone financial results for March 31, 2025, and March 31, 2026, were correctly reported and remain unchanged.

- Board approved setting up "Gaudium Women Hospital, Lucknow" in Uttar Pradesh. - The project involves a 30-year land lease with 10% net revenue share and a ₹3 crore security deposit. - Estimated project cost is up to ₹15 crore for development and operationalization.

- Concall Schedule - Concall Date: June 12, 2026 - Concall Time: 11:00 AM to 12:00 PM - Details: Virtual meeting with InsightX Conference, organized by Choice Broking. No unpublished price sensitive information will be shared.

Gaudium IVF and Women Health Limited has informed the exchanges about the availability of the audio recording of its Earnings Call. The call discussed the Audited Standalone and Consolidated Financial Results for the quarter and year ended March 31, 2026, and was held on May 29, 2026. The recording is accessible on the company's website.

Consolidated Revenue from Operations ₹30.35 Cr vs ₹26.92 Cr (▲12.74% YoY), EBITDA ₹12.17 Cr vs ₹8.72 Cr (▲39.56% YoY), PAT ₹8.36 Cr vs ₹6.45 Cr (▲29.46% YoY). EBITDA Margin 40.10% vs 32.39% (▲771 bps). The company also integrated AI-led embryology platforms in April 2026 and plans expansion into new IVF hubs.

Gaudium IVF and Women Health Limited reported strong Q4 FY26 consolidated results. Revenue from operations increased to ₹30.35 Cr from ₹26.92 Cr (▲12.73% YoY). EBITDA grew to ₹12.17 Cr from ₹8.72 Cr (▲39.56% YoY), and Net Profit (PAT) rose to ₹8.36 Cr from ₹6.46 Cr (▲29.45% YoY). EBITDA margin expanded significantly to 40.11% from 32.39% (▲772bps).

Gaudium IVF and Women Health Limited informed that the National Company Law Tribunal (NCLT), New Delhi Bench, vide its order dated May 15, 2026, rejected the petition filed by M/s. Ramaa Capital (Operational Creditor) against the company under the Insolvency and Bankruptcy Code, 2016. The company received the order on May 22, 2026, and stated that this outcome has no impact on its financial, operational, or other activities.

Gaudium IVF and Women Health Limited announced an Earnings Conference Call to discuss its Audited Standalone and Consolidated Financial Statements/Results for the quarter and year ended March 31, 2026. The call is scheduled for Friday, May 29, 2026, at 12:00 P.M. IST.